US biopharma company Soligenix has wrapped up enrolling patients for its phase 3 Fluorescent Light Activated Synthetic Hypericin clinical trial (FLASH clinical trial) for SGX301 (synthetic hypericin) in cutaneous T-cell lymphoma (CTCL). The late-stage study enrolled 169 subjects in the FLASH clinical trial. This was after Soligenix secured positive interim analysis, which included a prospectively […]
Continue reading …
Innovent Biologics and Beijing Hanmi Pharmaceutical, a subsidiary of Hanmi Pharmaceutical, said that the first patient has been dosed in a phase 1 clinical trial in China for evaluating IBI315 for the treatment of advanced solid malignancies. IBI315, which has been co-developed by the companies, is a recombinant fully human bispecific antibody targeting programmed cell […]
Continue reading …ALTA-1L trial results : Takeda’s ALUNBRIG continues to show superiority over crizotinib
November 23, 2019 No Comment
ALTA-1L trial results : Takeda Pharmaceutical says that ALUNBRIG (brigatinib), its tyrosine kinase inhibitor (TKI), is continuing to show superiority over crizotinib in the phase 3 ALTA-1L trial. The Japanese pharma company released updated data from the late-stage trial involving adult patients having advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who did […]
Continue reading …
Viking Therapeutics has initiated the VOYAGE study, a phase 2b clinical trial of its liver-selective thyroid hormone receptor beta agonist VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). The California-based biopharma company said that clinical trial sites have been opened for enrolling patients after it got clearance of investigational new drug (IND) application for the NASH […]
Continue reading …resTORbio to stop RTB101 development for symptomatic respiratory illness
November 18, 2019 No Comment
resTORbio has discontinued the development of RTB101, a TORC1 inhibitor, for the prevention of clinically symptomatic respiratory illness (CSRI) after the drug failed to meet the primary endpoint of the PROTECTOR 1 Phase 3 study. The US biopharma company was conducting the PROTECTOR 1 clinical trial for assessing the safety and efficacy of RTB101 for […]
Continue reading …
WIRB-Copernicus Group (WCG), a clinical services organization, said that its clinical services division has acquired Waife & Associates (W&A), a provider of management consulting services for biopharma clinical research clients. Financial terms of the acquisition were not disclosed by the parties. Waife & Associates is engaged in making clinical development more efficient and productive by […]
Continue reading …LAVENDER phase 3 clinical trial launched for trofinetide in Rett syndrome by Acadia Pharmaceuticals
October 31, 2019 No Comment
US biopharma company Acadia Pharmaceuticals has launched the LAVENDER phase 3 clinical trial to evaluate the efficacy and safety of trofinetide for the treatment of Rett syndrome in girls and young women. Rett syndrome is considered to be a serious and rare neurodevelopmental congenital disorder related to the central nervous system (CNS). Symptoms of Rett […]
Continue reading …Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma
October 30, 2019 No Comment
Cellectis said that it has dosed the first patient in a phase 1 study – the MELANI-01 clinical trial to evaluate UCARTCS1, an allogeneic off-the-shelf CAR-T product candidate for the treatment of relapsed/refractory multiple myeloma (R/R MM). The French gene therapy company began the phase 1 dose-escalation study after getting clearance from the US Food […]
Continue reading …
Arena Pharmaceuticals has dosed the first subject in the phase 2 ADVISE clinical trial, which is evaluating etrasimod for the treatment of moderate-to-severe atopic dermatitis (AD). Etrasimod is a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator. Atopic dermatitis is considered to be a serious, chronic immune-mediated disease in which symptoms are varied. However, the usual […]
Continue reading …
Investigational NMIBC treatment TBC-1002 : LIPAC Oncology said that it has wrapped up a phase 1 clinical trial of TBC-1002 for the treatment of non-muscle invasive bladder cancer (NMIBC) and has now initiated a phase 2 A clinical trial. The US pharma company, which is a subsidiary of California-based TesoRx Pharma, said that the phase […]
Continue reading …
Business News Today
- TASI acquires German inspection systems manufacturer Cassel Messtechnik
- ALX Oncology raises $105m to advance clinical development of ALX148
- ImmunogenX enrolls patients for Solutions for Celiac trial of Latiglutenase
- McDermott wins contract for six crude oil storage tanks in Texas
- Badin IV South Block, Pakistan : Petroleum Exploration, Jura Energy begin commercial production
- Google wraps up $2.6bn acquisition of data platform company Looker
- ABG buys majority stake in spirits distribution company Indie Brands
- Arthur J. Gallagher acquires Illinois-based Affiliated Benefit Consultants
- Pinpoint Therapeutics secures funds for developing autophagy inhibitors for cancer
- Antios Therapeutics begins phase 1 trial for ATI-2173, a chronic hepatitis B candidate
